The Tuberous Sclerosis Complex

Peter B. Crino, M.D., Ph.D., Katherine L. Nathanson, M.D., and Elizabeth Petri Henske, M.D.

From the Department of Neurology (P.B.C.) and the Division of Medical Genetics (K.L.N.), University of Pennsylvania Medical Center; and the Department of Medical Oncology, Fox Chase Cancer Center (E.P.H.) — both in Philadelphia. Address reprint requests to Dr. Crino at the Department of Neurology, 3 West Gates Bldg., 3400 Spruce St., University of Pennsylvania Medical Center, Philadelphia, PA 19104, or at peter.crino@uphs.upenn.edu.

Drs. Crino and Henske contributed equally to this article.

Copyright © 2006 Massachusetts Medical Society.

The tuberous sclerosis complex (TSC), a multisystem, autosomal dominant disorder affecting children and adults, results from mutations in one of two genes, TSC1 (encoding hamartin) or TSC2 (encoding tuberin) (see the Glossary). First described in depth by Bourneville in 1880,1 TSC often causes disabling neurologic disorders, including epilepsy, mental retardation, and autism. Additional major features of the disease include dermatologic manifestations such as facial angiofibromas, renal angiomyolipomas, and pulmonary lymphangiomyomatosis. TSC has a wide clinical spectrum of disease, and many patients have minimal signs and symptoms with no neurologic disability. With the discovery of the two genes responsible for TSC and insights derived from observations in Drosophila melanogaster models, our understanding of the pathogenesis of this disorder has progressed rapidly during the past decade. Clinical trials predicated on the cellular targets of hamartin and tuberin are under way.

The diagnostic criteria for TSC consist of a set of major and minor diagnostic features (Table 1). Cases meeting these criteria fulfill a clinical diagnosis of TSC; the results of molecular genetic testing of the TSC1 or TSC2 loci are currently viewed as corroborative. Many affected persons come to medical attention because of seizures or dermatologic manifestations. However, no single feature of TSC is diagnostic; thus, an evaluation that includes consideration of all clinical features is necessary to make the diagnosis. The clinical manifestations of TSC appear at distinct developmental points (Table 1). For example, cortical tubers and cardiac rhabdomyomas form during embryogenesis and thus are typical findings in infancy. Skin lesions are detected at all ages in more than 90% of patients with TSC. Hypopigmented macules (formerly known as ash-leaf spots) are generally detected in infancy or early childhood, whereas the so-called shagreen patch is identified with increasing frequency after the age of 5 years. Ungual fibromas typically appear after puberty and may develop in adulthood. Facial angiofibromas (Fig. 1A, 1B, and 1C), formerly called adenoma sebaceum, may be detected at any age but are generally more common in late childhood or adolescence. A subependymal giant-cell tumor of the brain may develop in childhood or adolescence. Renal cysts can be detected in infancy or early childhood, whereas angiomyolipomas develop in childhood, adolescence, or adulthood. Pulmonary lymphangiomyomatosis is found in adolescent girls or women with TSC.

Clinical manifestations of TSC have variable penetrance. For example, two underrecognized groups of patients are asymptomatic adults with one or two minor features who meet the diagnostic criteria on the basis of a physical examination, radiographic findings, or both and asymptomatic women who give birth to a child with early neurologic manifestations of TSC.
**Glossary**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAP</td>
<td>GTPase-activating protein; converts a Ras homologue protein from GTP (active state) to GDP (inactive state).</td>
</tr>
<tr>
<td>Hamartin</td>
<td>Protein product of the chromosome 9q34 TSC1 gene.</td>
</tr>
<tr>
<td>Loss of heterozygosity (LOH)</td>
<td>A DNA marker with a one-allele (homozygous) pattern in a tumor as compared with normal DNA, which has a two-allele (heterozygous) pattern.</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mammalian target of rapamycin (now called sirolimus); kinase activated by Rheb.</td>
</tr>
<tr>
<td>p70S6K</td>
<td>Ribosomal protein p70 S6 kinase; target of mTOR that activates translation.</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>FDA-approved agent that inhibits mTOR.</td>
</tr>
<tr>
<td>Rheb</td>
<td>Ras homologue; target of the GAP domain of tuberin.</td>
</tr>
<tr>
<td>S6</td>
<td>Ribosomal S6 protein; regulates protein translation.</td>
</tr>
<tr>
<td>Tuberin</td>
<td>Protein product of the chromosome 16p13 TSC2 gene.</td>
</tr>
</tbody>
</table>

**Renal Lesions**

Renal angiomylolipomas, benign tumors composed of abnormal vessels, immature smooth-muscle cells, and fat cells (Fig. 1D, 1E, and 1F), are bilateral, with multiple tumors in each kidney, in most patients with TSC. The estimated incidence of angiomylolipomas in TSC ranges from 55 to 75%. Angiomylolipomas may be detected by ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI). Because these tumors have abnormal vasculature and often contain aneurysms, spontaneous life-threatening bleeding is an important complication, especially when angiomylolipomas are 3 cm or greater in diameter. The rate of growth of angiomylolipomas varies among patients and lesions. For example, a longitudinal study of 25 boys and 35 girls with TSC showed that 75% had renal angiomylolipomas by the age of 10.5 years, and in 2 of the boys, the diameter of the angiomylolipomas increased by 4 cm in a year. In general, surgical resection is avoided whenever possible in order to preserve renal function; angiomylolipomas that are more than 3 to 4 cm in diameter can usually be treated successfully by embolization.

In addition to angiomylolipomas, epithelial renal lesions that include epithelial cysts, polycystic kidney disease, and renal-cell carcinomas may develop in patients with TSC. Epithelial cysts are generally asymptomatic and are more often associated with hypertension and renal failure than are angiomylolipomas. In addition, an estimated 2 to 3% of patients with TSC carry a contiguous germline deletion that affects both the TSC2 gene and one of the genes that leads to autosomal dominant polycystic kidney disease on chromosome 16p13, resulting in a polycystic kidney phenotype that is detectable in infancy or early childhood and that generally leads to renal insufficiency in the late teens to early 20s.

The overall incidence of renal carcinoma in patients with TSC is similar to that in the general population, with a lifetime risk of 2 to 3%; however, the cancer is diagnosed at a younger age in patients with TSC. In one series of patients with TSC, renal carcinoma developed at an average age of 28 years, 25 years earlier than the average age at diagnosis in the general population. There are case reports of renal carcinoma in children and even in one infant with TSC. An unusual feature of renal carcinoma associated with TSC is its pathological heterogeneity. Clear-cell, papillary, and chromophobe carcinoma subtypes, as well as oncocyotomas, have all been reported in patients with TSC. In one series, four of six patients died from metastases of renal carcinoma.

**Pulmonary Manifestations**

Lymphangiomatosis, also called lymphangioleiomyomatosis, affects women almost exclusively and is characterized by widespread pulmonary proliferation of abnormal smooth-muscle cells and cystic changes within the lung parenchyma (Fig. 1G, 1H, and 1I). Lymphangiomatosis is usually diagnosed during early adulthood and is initially manifested by dyspnea or pneumothorax. Radiographic evidence indicates that the incidence of lymphangiomatosis among women with TSC is 26 to 39%; many of these women are asymptomatic. In a series of 49 TSC-related deaths reported by the Mayo Clinic, lymphangiomatosis was cited as the cause of 4 deaths, making it the third most frequent cause of death after renal and brain lesions.

**Neurologic Manifestations**

The neurologic manifestations of TSC, which include epilepsy, cognitive disability, and neurobehavioral abnormalities, such as autism, appear to be intimately related to the cerebral cortical tubers (Fig. 2) that are present in over 80% of patients. Tubers are developmental abnormalities of the cerebral cortex characterized histologically by a loss of the normal six-layered structure of the cortex and by dysmorphic neurons, large astro-
cytes, and a unique type of cell known as a giant cell.21,22 Tubers have been identified in fetuses at a gestational age of 20 weeks.23 The lesions persist throughout life but do not become malignant tumors. Tubers can calcify or undergo cystic degeneration.

Epilepsy may be the most prevalent and challenging clinical manifestation of TSC. Epilepsy occurs in more than 70 to 80% of patients with TSC, and virtually all subtypes of seizure (simple partial, complex partial, and generalized tonic–clonic seizures) have been reported. Seizures are often refractory to treatment, even to polytherapy with antiepileptic drugs.24 Patients with medically refractory epilepsy may require a surgical evaluation.24,25 In most cases, the region in which the seizure originates coincides with the location of a tuber in the brain, and it is widely believed that tubers serve as the epileptogenic focus. Thus, intractable epilepsy is often treated by resection of a tuber.24,25

Infantile spasms, a devastating epileptic syndrome that is often associated with profound mental retardation and a poor neurologic prognosis, occurs in 20 to 30% of infants with TSC.18 Treatment with vigabatrin, an inhibitor of γ-aminobutyric acid transaminase, appears to be beneficial in some of these infants.18 Whether the association between infantile spasms and cognitive deficits arises from the effects of early seizures or by a distinct mechanism is unknown.26 The risk and degree of intellectual impairment correlate with the time from the initiation of treatment until the cessation of the spasms and the ability to control the seizures after infantile spasms, suggesting that the seizures themselves have some role in the severity of the subsequent neurologic deficits.26-28 Clinical studies have suggested that a higher number of tubers (more than seven) in patients with TSC is associated with the development of infantile spasms and intractable epilepsy; thus, the number of tubers may also be an independent risk factor for cognitive disability.21

In approximately 10% of patients with TSC, the growth of subependymal giant-cell tumors (Fig. 2) can cause obstruction of cerebrospinal fluid flow, hydrocephalus, increased intracranial pressure, and even death.29 These lesions are composed of proliferative astrocytes and giant cells but do not become malignant glial tumors.29 Subependymal giant-cell tumors are presumed to derive from subependymal nodules, which are asymptomatic hamartomas that protrude from the walls of the lateral and third ventricles.

### Cardiac Lesions
Cardiac rhabdomyomas are intracavitary or intramural tumors that are present in nearly 50 to 70% of infants with TSC but cause important clinical problems in only a very small fraction of those patients. Rhabdomyomas may be detected on fetal ultrasonography and are the most common cardiac tumor diagnosed in utero. The detection of a rhabdomyoma may be useful for making a pre-
The natal diagnosis of TSC. In one series of cases, rhabdomyoma was identified in 19 fetuses; the diagnostic criteria for TSC were met after birth in 15 (79%). In all 15 of those fetuses, multiple rhabdomyomas were detected, whereas the 2 fetuses with a single rhabdomyoma had no other diagnostic features of TSC. Rhabdomyoma may be associated with cardiac failure in infancy, and 47% of patients with rhabdomyoma have also had associated cardiac dysrhythmias, including atrial tachycardia, ventricular tachycardia, complete heart block, and the Wolff–Parkinson–White syndrome. Unlike other lesions seen in TSC, cardiac rhabdomyomas often disappear spontaneously in later life; in one series, for example, 20 of 24 patients with TSC had complete regression of the rhabdomyoma.

Figure 1. Dermatologic, Renal, and Pulmonary Manifestations of TSC.
A patient with facial angiofibromas around the nose and chin is shown at 4 years of age (Panel A), 8 years of age (Panel B), and 21 years of age (Panel C). The progression of the lesions over time is evident. Panel D shows a resected kidney distorted by numerous angiomyolipomas. Sections stained with hematoxylin and eosin show fat (arrow) and smooth muscle (Panel E) and aberrant vessels (Panel F). Computed tomography (Panel G) of the lungs shows the radiographic appearance of lymphangiomatosis. Smooth-muscle proliferation in lymphangiomatosis is shown after staining with hematoxylin and eosin (Panel H) and immunohistochemical labeling with muscle-specific actin (Panel I).

Molecular Genetics
Linkage analysis in multigenerational families and positional cloning were used to map both the TSC1 and TSC2 genes (Fig. 3). The TSC2 gene, which is located on chromosome 16p13, encodes a tran-
script of 5.5 kb containing 41 exons and encompassing 40 kb of genomic DNA; there are several alternatively spliced versions.\textsuperscript{35} The TSC1 gene, which is located on chromosome 9q34, encodes a transcript of 8.6 kb, containing 23 exons and encompassing 55 kb of genomic DNA.\textsuperscript{34}

Extensive studies of the TSC1 and TSC2 genes in patients with TSC have revealed a wide spectrum of mutations.\textsuperscript{33,34} Indeed, more than 200 TSC1 and nearly 700 TSC2 unique allelic variants have been reported (http://chromium.liacs.nl/lovd/index.php?select_db=TSC1 or db=TSC2).\textsuperscript{36-40} There are no particular regions within the TSC1 or TSC2 gene in which mutations occur at a high rate, although missense mutations at Arg611 (exon 16), Pro1675Leu (exon 38), and an 18-bp in-frame deletion in exon 40 have been observed in TSC2 in multiple patients.\textsuperscript{3,36,37} Missense mutations and large genomic deletions are much more frequent in TSC2 than in TSC1. Missense mutations in TSC2 tend to cluster in the GTPase-activating protein (GAP) binding domain (exons 35 through 39).\textsuperscript{41} A subgroup of large genomic deletions and rearrangements in TSC2 also affect the adjacent PKD2 gene, causing early-onset polycystic kidney disease.\textsuperscript{8,9}

Linkage studies initially suggested that there would be equivalent numbers of families with mutations in each TSC gene.\textsuperscript{42} However, the frequency of mutations reported in TSC2 is consistently higher than in TSC1; TSC1 mutations account for only 10 to 30% of the families identified with TSC.\textsuperscript{36-39,41,43} In sporadic cases of TSC, there is an even greater excess of mutations in TSC2. Indeed, in two large studies, mutations in TSC1 were identified in only about 15% of patients.\textsuperscript{3,37} Nonetheless, identification of TSC1 mutations appears to be twice as likely in familial cases as in sporadic cases. The disparity in mutational frequency may reflect an increased rate of germline and somatic mutations in TSC2 as compared with TSC1, as well as ascertainment bias, since mutations in TSC2 are associated with more severe disease.\textsuperscript{3,36,37}

Among patients meeting the clinical criteria for a diagnosis of TSC, 15 to 20% have no identifiable mutations.\textsuperscript{3,36} These persons generally have milder clinical disease (i.e., a lower incidence of mental retardation, seizures, and dermatologic signs) than patients with identified TSC1 or TSC2 mutations. Somatic mosaicism has been reported in some persons with mutations in TSC1 or TSC2 and is thought to account for a milder clinical phenotype. This is also a credible explanation for the failure to detect a mutation.\textsuperscript{44}

In agreement with Knudson’s two-hit tumor-suppressor gene model,\textsuperscript{45} inactivation of both alleles of either TSC1 or TSC2 appears to be required for lesion formation in TSC. Most second-hit mutations are large deletions involving the loss of surrounding loci. These mutations are referred to as loss of heterozygosity, since they affect neighboring heterozygous polymorphic markers. Loss of heterozygosity in TSC1 or TSC2 has been consistently observed in the majority of TSC-associated angiomyolipomas, cardiac rhabdomyomas, subependymal giant-cell tumors, and lymphangio-
Substantial progress has been made in the past 5 years toward understanding the normal cellular functions of the TSC1–TSC2 protein complex. Much of this progress has been deduced from studies in the fruit fly, D. melanogaster. The TSC1–TSC2 complex interacts with several proteins (Fig. 4), although in most cases the clinical relevance of these interactions is not yet well understood. One of the first mechanistic clues to the roles that TSC1 and TSC2 have in cell function was the finding that mutations in the drosophila Tsc1 and Tsc2 homologues increased cell and organ size. Subsequent experiments demonstrated that the TSC1–TSC2 heterodimer inhibits the mammalian target of rapamycin (mTOR) cascade. In normal cells, direct phosphorylation and inactivation of TSC2 by protein kinase B (AKT) leads to mTOR activation. A serine–threonine kinase, mTOR has a central role in the control of cell growth and proliferation through the regulation of ribosome biosynthesis and protein translation. It functions by phosphorylating two effector molecules — p70S6 kinase and 4E-binding protein 1 (4E-BP1) — to increase cell growth and proliferation in response to growth factors, amino acids, and nutrients. By phosphorylating ribosomal protein S6, p70S6 kinase causes increased ribosome biogenesis. The phosphorylation of 4E-BP1 permits messenger RNA (mRNA) translation. In TSC-associated tumors, loss of TSC1 or TSC2 results in mTOR-dependent phosphorylation of p70S6 kinase, ribosomal protein S6, and 4E-BP1.

Rheb (RAS-homologue expressed in brain), a member of the RAS superfamily, is a specific GTPase downstream of TSC2 that functionally links the TSC1–TSC2 complex to the mTOR pathway. Rheb, like other RAS family members, cycles between an active GTP-bound state and an inactive GDP-bound state. TSC2 stimulates the conversion of Rheb–GTP to Rheb–GDP, thereby inactivating Rheb. Loss of TSC2 function leads to enhanced Rheb–GTP signaling and mTOR activation. TSC2 mutations in the GAP domain have low GAP activity with respect to Rheb, suggesting that the GAP activity of TSC2 is essential for its physiologic function. Since patients with germ-line TSC1 mutations and those with TSC2 mutations have nearly identical phenotypes, it seems likely that TSC1 participates in the regulation of TSC2-related GAP activity with respect to Rheb, but the precise role of TSC1 is not yet clear. Given

myomatosis cells but has only rarely been found in cerebral cortical tubers. This observation may indicate that either inactivation of both alleles is not required for tuber pathogenesis or only a subgroup of cells within a tuber is affected by the second hit.

**Functions of TSC1 and TSC2**

**TSC Proteins and Interacting Factors**

TSC1 (hamartin), a 140-kD protein with no homology to TSC2 (Fig. 3). TSC2 encodes TSC2 (tuberin), a 200-kD protein with a GAP domain near the carboxy terminal (Fig. 3). TSC1 and TSC2 interact physically with high affinity to form heterodimers, an observation that is consistent with the similar clinical features of patients with TSC1 and TSC2 mutations. TSC1 and TSC2 are coexpressed in cells within multiple organs, including the kidney, brain, lung, and pancreas. TSC2 has been localized to the Golgi apparatus and the nucleus, and TSC1 to the centrosome.
the critical role of TSC1–TSC2 in the regulation of Rho and mTOR activation, it is not surprising that the complex is subject to an intricate and incompletely understood series of phosphorylation events.67-74

**TSC1–TSC2 SIGNALING AND CLINICAL MANIFESTATIONS OF TSC**

**ABERRANT DIFFERENTIATION IN RENAL ANGIOMYOLIPOMAS**

Loss of heterozygosity at the TSC1 or TSC2 locus and hyperphosphorylation of ribosomal protein S6 have been documented in each of the three components of angiomyolipomas (vessels, smooth muscle, and fat), suggesting that all three components arise from a common progenitor and that the TSC1–TSC2 complex regulates the differentiation of cells that are derived from mesenchyme. The smooth-muscle component of angiomyolipoma is histologically and immunophenotypically identical to the smooth-muscle cells of lymphangiomyomatosis, suggesting the existence of a pathogenic connection between the two disorders.

**THE “BENIGN METASTASIS” HYPOTHESIS**

Women with the sporadic form of lymphangiomyomatosis do not have germline TSC1 or TSC2 mutations.88 Approximately 60% of such patients have renal angiomyolipomas. In patients with both sporadic lymphangiomyomatosis and angiomyolipoma, identical somatic TSC2 mutations have been identified in the abnormal lung and kidney cells but not in the normal cells,89,90 suggesting that lymphangiomyomatosis and angiomyolipoma cells are genetically related and most likely arise from a common progenitor cell. These data have led to the “benign metastasis” hypothesis for the pathogenesis of lymphangiomyomatosis (Fig. 5), which proposes that histologically identical to the smooth-muscle cells of lymphangiomyomatosis, suggesting the existence of a pathogenic connection between the two disorders.

Cells lacking TSC1 or TSC2 have an altered capacity for motility and migration. The expression of TSC1 and TSC2 is associated with the activation of Rho, a small GTPase63,91 that regulates the actin cytoskeleton and focal adhesions, and TSC2-deficient smooth-muscle cells exhibit increased migration in vitro.58 These observations are consistent with a model in which TSC2-deficient cells have increased migratory potential. The fact that pulmonary lymphangioleiomyomatosis occurs only in women has led to the hypothesis that estrogen regulates TSC signaling and, perhaps, also the migration of TSC2-deficient cells. Furthermore, the carboxy terminal of TSC2 interacts with the estrogen receptor α and functions in vitro as a transcriptional corepressor of the estrogen receptor.59 However, the in vivo role of estrogen in the pathogenesis of this disease is not yet understood.

Figure 4. Interactions of the TSC1–TSC2 Complex with Multiple Cellular Pathways.

The TSC1–TSC2 protein complex integrates cues from growth factors, the cell cycle, and nutrients to regulate the activity of mTOR, p70S6 kinase (S6K), 4E-BP1, and ribosomal S6 (S6) proteins. Additional proteins known to interact with either TSC1 or TSC2 are shown: rapamycin, SI4-3-3, estrogen receptor α, calmodulin, p27, SMAD2 and SMAD3 (the human isoform homologues of Drosophila mothers against decapentaplegic), protein associated with Myc (PAM), cyclin-dependent kinase 1 (CDK1), and cyclin A and B.56-66 TSC1 and TSC2 have additional roles besides the modulation of mTOR. For example, Rheb–GTP inhibits B-Raf kinase67,68 in a rapamycin-independent manner, indicating that mTOR is not involved in this process. Multiple kinases phosphorylate and inactivate TSC2 and thereby activate Rho and mTOR: mitogen-activated protein kinase–activated protein kinase 2 (MK2),69 p90 ribosomal S6 kinase 1 (RSK1),70 and extracellular-related kinase 2 (ERK2).71 TSC1 is phosphorylated during the G2 and M phases of the cell cycle by CDK1, and phosphorylation-deficient TSC1 mutants result in enhanced inhibition of p70S6K, suggesting that the phosphorylation of TSC1 inhibits the activity of the TSC1–TSC2 complex.72 The activity of TSC1 and TSC2 can also be enhanced by phosphorylation. Under conditions of energy deprivation, TSC2 is phosphorylated and activated by AMP kinase (AMPK),73,74 and the phosphorylation of TSC1 by glycogen synthase kinase 3β (GSK3β) increases the stability of the TSC1–TSC2 complex.75
**Cell-Selective Activation of mTOR in Tubers and Subependymal Giant-Cell Tumors**

Analysis of surgically resected tubers has revealed cell-specific activation of the mTOR cascade in giant cells, as evidenced by the expression of activated (phosphorylated) components of the mTOR cascade, including phosphorylated p70S6 kinase and phosphorylated ribosomal protein S6 (Fig. 2).\(^{92,93}\) Since mTOR is a critical regulator of cell size, it is logical to infer that the activation of mTOR is responsible for cytomegaly in tubers and subependymal giant-cell tumors. Interestingly, subependymal giant-cell tumor cells show high levels of phosphorylated p70S6 kinase, phosphorylated ribosomal S6, and phosphorylated Stat3 proteins, which are also indicative of mTOR activation.\(^{46}\) The loss of heterozygosity detected in subependymal giant-cell tumors provides evidence that biallelic TSC gene inactivation leads to the activation of mTOR and to cytomegaly.\(^{46}\)

**Practical Management**

In most patients with TSC, the first management issue is making the appropriate diagnosis by identifying major and minor diagnostic features. For initial diagnostic evaluation, careful dermatologic examination of the skin, including use of a Wood’s lamp and funduscopic examination to identify retinal hamartomas, is necessary. In infants, echocardiography may reveal rhabdomyomas. MRI or CT of the brain is indicated to identify tubers and subependymal giant-cell tumors. Visualization of the kidneys by ultrasonography, CT, or MRI is warranted to identify angiomyolipomas. In women with TSC, CT of the lungs is indicated to look for subclinical lymphangiomyomatosis, and pul-

---

*Figure 5. Model of the Pathogenesis of Angiomyolipomas and Lymphangiomyomatosis.*

Molecular genetic data indicate that all three components of angiomyolipomas are derived from a common precursor cell. The pathogenetic mechanism of lymphangiomyomatosis involves the aberrant migration of smooth-muscle cells harboring a somatic TSC gene mutation to the lung. Because lymphangiomyomatosis occurs almost exclusively in women, estrogen may promote this migration, although the targeting mechanism is not yet understood. It has been hypothesized that cells with TSC1 or TSC2 mutations may travel to the lungs from angiomyolipomas in the kidney (indicated by a dashed arrow).
monary-function tests may provide a measure of disease progression. Currently, there are at least 15 TSC clinics across the United States that specialize in the diagnosis, care, and treatment of patients with the disorder. The clinical staff at these multidisciplinary centers includes specialists such as neurologists, dermatologists, geneticists, and pulmonologists. For the general practitioner, referring a patient to a regional TSC clinic should ensure that he or she will receive a comprehensive evaluation of the multisystem complications in TSC. If referral to a TSC clinic is not feasible, then subspecialty evaluation of the patient for individual manifestations of TSC, including lymphangiomyomatosis, angiomyolipomas, and epilepsy, is prudent. Physicians and patients can also gain useful information from the Tuberous Sclerosis Alliance Web site (www.tsalliance.org).

The second important issue in the management of TSC is long-term follow-up, including the monitoring of lesion growth. In particular, the growth of angiomyolipomas or subependymal giant-cell tumors requires continued vigilance. No conclusive guidelines for surveillance have been established for this disease, but most centers periodically image the brain and abdomen to monitor the growth of lesions in the brain and kidney. (The Tuberous Sclerosis Alliance provides suggestions for surveillance on its Web site at www.tsalliance.org/pages.aspx?content=10.) For example, it is standard practice to perform brain and abdominal imaging at least every 3 years, and more often in patients with brain or renal lesions that have progressive growth. Annual MRI of the brain is suggested in patients until they are at least 21 years of age, and then MRI should be done every 2 to 3 years both to diagnose and to monitor subependymal giant-cell tumors. In patients with multiple angiomyolipomas or a single lesion that is progressive, yearly ultrasonography, MRI, or CT is indicated.

In patients with lymphangiomyomatosis, annual pulmonary-function testing may be useful to monitor lung function, and some patients may require more frequent assessments. Although electroencephalography is not part of the diagnostic workup for TSC, it remains an important tool in patients with TSC and epilepsy to define background cerebral activity, characterize patterns such as hypersynchrony in infantile spasms, and identify seizure foci. Periodic dermatologic evaluation is useful, since facial angiofibromas can cause cosmetic disfiguration and ultimately require laser therapy or surgical removal. In general, lifetime surveillance for lesion growth in patients with TSC permits early recognition of potentially life-threatening complications.

Finally, genetic counseling should be offered to patients to aid with family planning. TSC is an autosomal dominant disorder; thus, those affected should be advised that the risk of having an affected child is approximately 50%. Genetic testing for TSC1 and TSC2 mutations is commercially available. Prenatal or preimplantation genetic testing is becoming more widely available.

**Therapeutic Developments**

Since tumor cells from patients with TSC activate mTOR, the mTOR inhibitor sirolimus has been identified as a potential therapeutic agent. Preclinical studies in mice have supported the usefulness of this approach; clinical trials of sirolimus in patients with TSC and in those with sporadic cases of lymphangiomyomatosis are ongoing. A recent study demonstrated regression of subependymal giant-cell tumors in patients after sirolimus therapy. One concern is that sirolimus treatment may restore the cell’s ability to activate AKT, suggesting that long-term treatment may increase the risk of malignant tumors in patients with TSC. Clearly, both the short- and long-term consequences of mTOR inhibition in such patients require further study.

**Conclusions**

The TSC1–TSC2 complex plays a central role in the integration of multiple cues to regulate cellular growth and differentiation, and mutations in TSC1 or TSC2 result in widespread, devastating consequences. Key priorities for future research include elucidating the location of and functional relationship between TSC1 and TSC2 and their pathways, determining whether Rheb is the sole downstream effector of the TSC1–TSC2 complex and whether mTOR is the only clinically relevant target of Rheb, understanding the relationship between tubers and epilepsy, and investigating the role of estrogen in the pathogenesis of lymphangiomyomatosis. The recent delineation of the TSC biochemical signaling pathway suggests strategies for developing targeted therapies including mTOR inhibition, which is being evaluated in clinical trials.
Supported by grants from the National Institutes of Health (N045021, to Dr. Crino, and DK5052 and HL66746, to Dr. Henske).

No potential conflict of interest relevant to this article was reported.

REFERENCES


64. New England Journal of Medicine 2006;355:13


Copyright © 2006 Massachusetts Medical Society.

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF CHICAGO LIBRARIES on May 28, 2013. For personal use only. No other uses without permission.

Copyright © 2006 Massachusetts Medical Society. All rights reserved.